Show simple item record

dc.contributor.authorGarvey, J P
dc.contributor.authorBrown, C M
dc.contributor.authorChotirmall, S H
dc.contributor.authorDorman, A M
dc.contributor.authorConlon, P J
dc.contributor.authorWalshe, J J
dc.date.accessioned2011-04-05T14:44:59Z
dc.date.available2011-04-05T14:44:59Z
dc.date.issued2009-11
dc.identifier.citationTrimethoprim-sulfamethoxazole induced acute interstitial nephritis in renal allografts; clinical course and outcome. 2009, 72 (5):331-6 Clin. Nephrol.en
dc.identifier.issn0301-0430
dc.identifier.pmid19863874
dc.identifier.urihttp://hdl.handle.net/10147/127236
dc.description.abstractAcute interstitial nephritis (AIN) secondary to trimethoprim-sulfamethoxazole (TMP-SMX) is well documented as a cause of acute renal failure in native kidneys. TMP-SMX is the standard prophylactic agent against pneumocystis carinii (PCP) used in the early post-transplant period, however, it has to date only been indirectly associated with AIN in renal allografts. DESIGN, SETTING, PARTICIPANTS AND MEASUREMENTS: We describe eleven renal transplant patients with acute allograft dysfunction in whom a transplant biopsy demonstrated primary histopathologic features of allergic AIN, all of whom were receiving TMP-SMX in addition to other medications known to cause AIN.
dc.description.abstractAll cases occurred within 1 month of transplantation and accounted for 2.12% (11/518) of the total number of transplant biopsies performed during the study period. However, this figure increased to 10.1% (11/109) when those biopsies performed for early allograft dysfunction (< 1 month) were taken into account. After discontinuation of TMP- SMX alone, all patients had an immediate improvement in serum creatinine with excellent long term allograft function - mean improvement of serum creatinine from 465 micromol/l to 136 micromol/l at last follow-up (range 15 - 55 months).
dc.description.abstractAIN secondary to TMP-SMX, although an uncommon cause of allograft dysfunction over the study period, accounted for over 10% of cases of allograft dysfunction within the first month of transplantation. Therefore, a high degree of clinical suspicion for TMP-SMX-induced AIN is warranted when confronted with early acute allograft dysfunction.
dc.language.isoenen
dc.subject.meshAcute Disease
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAnti-Infective Agents
dc.subject.meshCreatinine
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshImmunosuppressive Agents
dc.subject.meshKidney
dc.subject.meshKidney Transplantation
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNephritis, Interstitial
dc.subject.meshTrimethoprim-Sulfamethoxazole Combination
dc.titleTrimethoprim-sulfamethoxazole induced acute interstitial nephritis in renal allografts; clinical course and outcome.en
dc.typeArticleen
dc.contributor.departmentDepartment of Nephrology, Beaumont Hospital, Dublin, Ireland.en
dc.identifier.journalClinical nephrologyen
dc.description.provinceLeinster
html.description.abstractAcute interstitial nephritis (AIN) secondary to trimethoprim-sulfamethoxazole (TMP-SMX) is well documented as a cause of acute renal failure in native kidneys. TMP-SMX is the standard prophylactic agent against pneumocystis carinii (PCP) used in the early post-transplant period, however, it has to date only been indirectly associated with AIN in renal allografts. DESIGN, SETTING, PARTICIPANTS AND MEASUREMENTS: We describe eleven renal transplant patients with acute allograft dysfunction in whom a transplant biopsy demonstrated primary histopathologic features of allergic AIN, all of whom were receiving TMP-SMX in addition to other medications known to cause AIN.
html.description.abstractAll cases occurred within 1 month of transplantation and accounted for 2.12% (11/518) of the total number of transplant biopsies performed during the study period. However, this figure increased to 10.1% (11/109) when those biopsies performed for early allograft dysfunction (< 1 month) were taken into account. After discontinuation of TMP- SMX alone, all patients had an immediate improvement in serum creatinine with excellent long term allograft function - mean improvement of serum creatinine from 465 micromol/l to 136 micromol/l at last follow-up (range 15 - 55 months).
html.description.abstractAIN secondary to TMP-SMX, although an uncommon cause of allograft dysfunction over the study period, accounted for over 10% of cases of allograft dysfunction within the first month of transplantation. Therefore, a high degree of clinical suspicion for TMP-SMX-induced AIN is warranted when confronted with early acute allograft dysfunction.


This item appears in the following Collection(s)

Show simple item record